ArticleTranslational cancer research2025
Genetic insights into colorectal cancer pathogenesis: a multi-omics and immunity perspective.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated multi-omics characterization of SPTBN2 overexpression reveals its pro-tumorigenic role and immune microenvironment remodeling in colorectal cancer.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a global health issue influenced by both genetic and environmental factors. Identifying key genes closely associated with CRC is crucial for understanding its pathological mechanisms and discovering therapeutic targets. This study aimed to integrate multi-omics datasets and Mendelian randomization (MR) approaches to identify CRC-related genes and to clarify their roles in tumor immunity and therapeutic potential. Methods: This is a cross-sectional study. We utilized databases such as Gene Expression Omnibus (GEO), Finnish National Genome Project (FinnGen), expression Quantitative Trait Loci (eQTL), and The Cancer Genome Atlas (TCGA), and employed MR, summary-data-based MR (SMR), and gene expression analyses to screen genes related to CRC development. Through immune cell infiltration analysis and mediation MR, we explored the relationship between these genes, tumor immunity, and immunotherapy. Results: Our study identified Conclusions: Our findings reveal how these genes contribute to CRC pathogenesis by modulating the immune microenvironment, providing important biomarkers and targets for the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.